Where is Amicus Therapeutics headquarters?
Amicus Therapeutics, a global patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases, is headquartered in Philadelphia, Pennsylvania, United States. From its central corporate executive offices, the company manages its international business, clinical research, and commercial operations. The Philadelphia headquarters serves as the primary strategic site for overseeing the development of its portfolio of specialized therapies, including innovative oral medicines and biological treatments designed for patients living with rare metabolic disorders. By situating its leadership and administrative functions in Philadelphia, the company benefits from its proximity to major academic research centers and biotechnology talent pools, enabling effective collaboration as it continues to advance its therapeutic pipeline to address significant unmet medical needs in the rare disease community.
Related FAQs
Several key therapeutic products developed and commercialized by Amicus Therapeutics have received official approval from the United States Food and Drug Administration, alongside regulatory clearances from international health authorities.
The head office of Amicus Therapeutics is located in Philadelphia, Pennsylvania, United States. This central office serves as the corporate and executive command hub, coordinating the global activities of the biotechnology enterprise.
Amkor Technology, a leading provider of semiconductor packaging and test services, maintains a global workforce of approximately 30,800 employees.
Amicus Therapeutics entered into a definitive merger agreement to be acquired by BioMarin Pharmaceutical in an all-cash transaction valued at approximately $4.8 billion.
Forcht Bank operates as a privately held regional community banking institution serving numerous communities across Kentucky, holding hundreds of millions of dollars in total assets and customer deposits.
Amrize operates with a specialized professional team tailored to its specific regional commercial footprint, typically comprising a targeted group of management and operational personnel.
Market evaluations of Fold Holdings (FLD) reflect the high-beta, speculative nature of equities tied closely to digital asset adoption, consumer reward card programs, and cryptocurrency treasury strategies.
Amitabh Bachchan did not buy Swiggy in its entirety, but his family office acquired a minority stake in the food delivery and quick commerce app in August 2024.
Amicus Therapeutics is recognized as a legitimate and respected global biotechnology company dedicated to discovering and delivering advanced medicines for individuals suffering from rare metabolic and genetic diseases.
Amicus Therapeutics functions as a dedicated biopharmaceutical enterprise focusing on the discovery, development, and commercialization of advanced medicines for individuals affected by rare and orphan metabolic diseases.
Amicus Therapeutics officially completed its initial public offering and began trading its common stock on the NASDAQ global market under the ticker symbol FOLD on February 8, 2007.
Amicus Therapeutics, Inc.
Following the completion of its merger acquisition by BioMarin Pharmaceutical, Amicus Therapeutics officially requested the voluntary withdrawal and delisting of its common stock from the Nasdaq stock market.
Fold Holdings, Inc. operates as a publicly traded enterprise listed on the NASDAQ exchange under the ticker symbol FLD, recognized as a specialized bitcoin financial services and rewards platform.
Amicus Therapeutics generates robust annual revenues hovering around $630 million USD (or approximately £470 million), driven by strong global commercial sales of its specialized rare disease therapies.
Amicus Therapeutics, Inc. trades on the NASDAQ global select market under the official stock ticker symbol FOLD.
Fortum operates as a prominent Nordic energy company headquartered in Finland, generating its revenue through the production and sale of clean electricity, heat, and related technical services.
BioMarin Pharmaceutical officially completed its landmark acquisition of Amicus Therapeutics in an all-cash transaction valued at approximately $4.8 billion.
Amicus Therapeutics continued its advancement as a global biotechnology leader focused on discovering, developing, and delivering breakthrough medicines for rare metabolic conditions such as Fabry disease and Pompe disease.